Associations of deoxyfructosazine and a sulfonyl urea antidiabetic agent have a synergistic activity in the treatment of type 2 diabetes

An association of deoxyfructosazine (2-((1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)-5-(2'S,3'R)(2',3',4'-trihydr oxybutyl pyrazine)) (I) and a sulfonyl urea antidiabetic agent (II) is new. Independent claims are also included for: (1) pharmaceutical compositions containing (I); an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	EVERS MICHEL
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An association of deoxyfructosazine (2-((1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)-5-(2'S,3'R)(2',3',4'-trihydr oxybutyl pyrazine)) (I) and a sulfonyl urea antidiabetic agent (II) is new. Independent claims are also included for: (1) pharmaceutical compositions containing (I); and (2) their use in the prevention and/or treatment of type 2 diabetes and its complications. La présente invention concerne l'association de déoxyfructosazine et d'un antidiabétique de la famille des sulfonylurées, les compositions pharmaceutiques contenant cette association et leur utilisation dans la prévention et/ ou le traitement du diabète de type 2 et ses complications.